Composition of mannuronic diacid

Patent metadata

Field	Value
Publication number	US-2020385417-A1
Application number	US-201716474928-A
Country	US
Kind code	A1
Filing date	Dec 27, 2017
Priority date	Dec 30, 2016
Publication date	Dec 10, 2020
Grant date	—

Abstract

The present invention relates to a mannuronic diacid oligosaccharide composition, comprising a mannuronic diacid of Formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 9, m is 0, 1 or 2, and m′ is 0 or 1, and wherein the total weight of mannuronic diacids wherein n=1-5 is 80-95% of the total weight of the composition, and the ratio of the total weight of mannuronic diacids wherein n=1-3 to the total weight of mannuronic diacids wherein n=4-7 is between 1.0 and 3.5.

First claim

1 . A mannuronic diacid oligosaccharide composition, comprising a mannuronic diacid of Formula (III) or a pharmaceutically acceptable salt thereof:

wherein n is an integer from 1 to 9, m is 0, 1 or 2, and m′ is 0 or 1,
and wherein,
the total weight of mannuronic diacids wherein n=1-5 is 80-95% of the total weight of the composition; and
the ratio of the total weight of mannuronic diacids wherein n=1-3 to the total weight of mannuronic diacids wherein n=4-7 is between 1.0 and 3.5.

2 . The mannuronic diacid oligosaccharide composition according to claim 1 , wherein the total weight of mannuronic diacids wherein m+m′=1 or 2 is not less than 50% or more, preferably 60-90%, more preferably 70-90% of the total weight of the composition.

3 . The mannuronic diacid oligosaccharide composition according to claim 2 , wherein the total weight of mannuronic diacids wherein m+m′=1 is not less than 10%, preferably 30-40% of the total weight of the composition.

4 . The mannuronic diacid oligosaccharide composition according to claim 1 , wherein the total weight of mannuronic diacids wherein m+m′=2 is not less than 10%, preferably 30-50% of the total weight of the composition.

5 . The mannuronic diacid oligosaccharide composition according to claim 1 , wherein the total weight of the mannuronic diacids wherein n=1-5 is 80-95% of the total weight of the composition.

6 . The mannuronic diacid oligosaccharide composition according to claim 1 , wherein the total weight of the mannuronic diacids wherein n=1-3 is 20-70% of the total weight of the composition.

7 . The mannuronic diacid oligosaccharide composition according to claim 1 , wherein the ratio of the total weight of the mannuronic diacids wherein n=1-3 to the total weight of the mannuronic diacids wherein n=4-7 is between 1.0 and 3.5.

8 . The mannuronic diacid oligosaccharide composition according to claim 7 , wherein the ratio of the total weight of the mannuronic diacids wherein n=1-3 to the total weight of the mannuronic diacids wherein n=4-7 is between 1.0 and 3.0.

9 . The mannuronic diacid oligosaccharide composition of claim 1 , wherein the weight percentages of mannosonic diacids with difference polymerization degrees in the composition are: 5-25% disaccharide, 15-30% trisaccharide, 15-25% tetrasaccharide, 10-25% pentasaccharide, 5-15% hexasaccharide, 3-10% heptasaccharide, 2-5% octasaccharide, 1-5% nonasaccharide, and 1-5% decasaccharide.

10 . The mannuronic diacid oligosaccharide composition according to claim 9 , wherein the weight percentages of mannosonic diacids with difference polymerization degrees in the composition are: 10-20% disaccharide, 18-30% trisaccharide, 15-25% tetrasaccharide, 15-20% pentasaccharide, 5-10% hexasaccharide, 3-5% heptasaccharide, 2-3% octasaccharide, 1-3% nonasaccharide, and 1-3% decasaccharide.

11 . The mannuronic diacid oligosaccharide composition of claim 1 , wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.

12 . A pharmaceutical composition or health care product, comprising an effective amount of the mannuronic diacid oligosaccharide composition of claim 1 , and, if necessary, a suitable carrier.

13 - 14 . (canceled)

15 . A method for treating a patient with senile dementia, comprising administering an effective amount of the mannuronic diacid oligosaccharide composition of claim 1 to a patient in need thereof.

16 . A method for preparing a mannuronic diacid oligosaccharide and a composition thereof by ozone oxidative degradation, by which the components or composition as defined in claim 1 is prepared.

17 . The method for preparing an oligosaccharide and a composition thereof by ozone oxidative degradation according to claim 16 , wherein: the oxidation reaction is carried out at a temperature of 0-70° C.; the oxidative degradation step is carried out at a pH of 3-13.

18 . The method for preparing an oligosaccharide and a composition thereof by ozone oxidative degradation according to claim 16 , wherein: the oxidation reaction is carried out at a temperature of 10-45° C.; the oxidative degradation step is carried out at a pH of 4-10.

Assignees

• Shanghai Green Valley Pharmaceutical Co Ltd
• Shanghai Inst Materia Medica Cas

Inventors

• Geng Meiyu
• Ding Jian
• Zhang Zhenqing
• Xiao Zhongping
• Du Xiaoguang
• Xin Xianliang

Classifications

• C07H1/00 Primary

  Processes for the preparation of sugar derivatives · CPC title

• C08B37/00

  Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof (cellulose D21; {microbiological processes C12P}) · CPC title

• C07H3/04

  Disaccharides · CPC title

• C07H3/06

  Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title